Eight-Year Survival Analysis of Patients With Dilated Cardiomyopathy: Does Treatment Era Affect Prognosis?
Lukas Kucera1, Martin Chudý1, Marcela Danková1
1Department of Heart Failure and Heart Transplantation, Faculty of Medicine, Comenius University, Bratislava, SVK.
Insights
Dilated cardiomyopathy (DCM) survival remained stable despite recent patients having more severe disease. Older age, advanced kidney disease, and higher NT-proBNP levels predict worse outcomes in DCM patients.
Area of Science:
- Cardiology
- Heart Failure Research
Background:
- Dilated cardiomyopathy (DCM) is a primary cause of heart failure (HF).
- Understanding long-term survival and prognostic factors in DCM is crucial for patient management.
Purpose of the Study:
- To retrospectively analyze long-term survival in patients with DCM.
- To investigate the impact of various clinical factors on DCM prognosis over different time periods.
Main Methods:
- Retrospective analysis of 622 DCM patients.
- Comparison of survival rates between cohorts diagnosed in 2016-2019 and 2020-2023.
- Multivariable analysis to identify independent predictors of survival.
Main Results:
- Overall survival was comparable between the two periods (p=0.856), with the later period reflecting shorter follow-up.
- Patients diagnosed between 2020-2023 exhibited a higher prevalence of NYHA class III/IV and larger ventricular diameters.
- Independent negative predictors for survival included older age, NYHA class III/IV, CKD stages 3-5, diabetes, and elevated NT-proBNP (>3000 ng/L).
- Female sex and overweight status were associated with improved survival.
Conclusions:
- Survival rates for DCM patients have remained stable, even with a recent increase in patient severity.
- Clinical factors like age, disease severity, comorbidities (CKD, diabetes), and NT-proBNP levels significantly influence DCM prognosis.
- The findings suggest a need for continued monitoring and tailored management strategies for DCM patients, considering potential influences like the COVID-19 pandemic.
Abstract:
Background Dilated cardiomyopathy (DCM) is a leading cause of heart failure (HF). We retrospectively analyzed long-term survival in DCM and the impact of clinical factors on their prognosis. Methods This was a retrospective analysis of 622 DCM patients (484 men, 138 women). Survival was compared between the 2016-2019 and 2020-2023 cohorts. Results The mean age was similar between cohorts (54 ± 13 vs. 55 ± 13 years). Mean overall survival for the entire cohort was 84.1 ± 1.6 months (95% CI: 81.0-87.4). When analyzed by period, mean survival was 84.1 ± 2.0 months (95% CI: 80.3-87.9) for patients diagnosed between 2016 and 2019 and 53.4 ± 1.1 months (95% CI: 51.2-55.6) for those diagnosed between 2020 and 2023. The difference was not statistically significant (log-rank p = 0.856). The shorter mean survival in the later period reflects the limited follow-up time due to ongoing observation. In the 2020-2023 group, a higher proportion of patients were classified as New York Heart Association (NYHA) III/IV (56% vs. 48%, p = 0.036) and had larger ventricular diameters (left ventricular end-diastolic diameter (LVEDD): 68 ± 8 mm vs. 66 ± 7 mm, p = 0.001; right ventricle (RV): 36 ± 7 mm vs. 34 ± 6 mm, p = 0.001). Treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) did not significantly affect survival. Multivariable analysis identified older age, NYHA class III/IV, chronic kidney disease (CKD) stages 3-5, diabetes, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >3000 ng/L as independent negative predictors, while female sex and overweight status were associated with better survival. Multivariable analysis identified older age, NYHA III/IV, CKD stages 3-5, diabetes, and NT-proBNP >3000 ng/L as independent negative predictors. Female sex and overweight status were associated with improved survival. Conclusions Survival in DCM patients remained stable across time periods, despite a higher-risk profile in recent years, potentially influenced by the COVID-19 pandemic.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cancer Survival Analysis
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Cardiomyopathy VI: Nursing Management


